10:48 AM EDT, 07/12/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Friday that the Leqembi has been approved in Israel for the treatment of patients with Alzheimer's disease.

The drug should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, according to the joint statement.

Leqembi's approval is based on results from the phase three Clarity AD study and is the first approved drug that reduces the rate of disease progression and slows cognitive and functional decline through this mechanism, the statement added.

The companies said that Eisai will commercialize the drug in Israel.

Price: 231.79, Change: -5.01, Percent Change: -2.12